Fig. 4

Effects of olomoucine treatment on markers of reactive astrogliosis at 7 days after stroke. A Vimentin: upper left image shows representative lanes from a blot comparing samples containing the infarct and peri-infarct tissue (I) and equivalent tissue from the contralateral hemisphere (C) from two rats; the upper right image shows representative lanes from a blot of infarct plus peri-infarct tissue from two rats treated with olomoucine (O) and two treated with vehicle (V). The bar graph shows the effect of olomoucine treatment on intensity of the vimentin band expressed relative to total protein in that sample. *p < 0.05 (Student’s t test). B GFAP: representative lanes from a blot of infarct plus peri-infarct tissue from two rats treated with olomoucine (O) and two treated with vehicle (V). The bar graph shows the effect of olomoucine treatment on the pooled data for intensity of the GFAP band expressed relative to total protein in that sample. The treatment did not produce a statistically significant difference in GFAP content (Student’s t test). C Neurocan: representative lanes from a blot of infarct plus peri-infarct tissue from two rats treated with olomoucine (O) or two treated with vehicle (V). The bar graph shows the effect of olomoucine treatment on the intensity of the bands for full-length neurocan (approx. 250 kDa) expressed relative to that of a proteolytic fragment of this protein (approx. 150 kDa). The treatment did not produce a statistically significant difference in this ratio (Student’s t test). Group results in panels A to C are shown as mean ± SD (n = 6 to 7 per group). Additional file 1: Fig. S1 and S3 shows the full blots including the representative lanes for treatment effects in panels A to C